aUNC Eshelman School of Pharmacy, Division of Pharmacotherapy and Experimental Therapeutics, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill
bDuke Cancer Institute
cDepartment of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, North Carolina
dUniversity of Chicago Comprehensive Cancer Center, Chicago, Illinois
eDepartment of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Florida, USA
fCenter for Genomic Medicine, RIKEN, Yokohama
gRIKEN Center for Integrative Medical Sciences, Yokohama, Japan
Correspondence to Federico Innocenti, MD, PhD, University of North Carolina at Chapel Hill, Eshelman School of Pharmacy, Lineberger Comprehensive Cancer Center, 1014 Genetic Medicine Building, CB 7361, 120 Mason Farm Road, Chapel Hill, NC 27599-7361, USA Tel: +1 919 966 9422; fax: +1 919 966 5863; e-mail: [email protected]
Received May 22, 2018
Accepted February 11, 2019